Cancer associated fibroblasts (CAFs) are specialized cells that drive fibrosis by secreting excess collagen into the tumor microenvironment.
Scartec has developed a proprietary platform to identify novel targets that can stop the activation of cancer-associated fibroblasts (CAFs).
Reversing fibrosis will improve T-cell infiltration/ drug access to cancer cells